Is BARD1 p.Pro89Gln (c.266C>A) pathogenic?

BARD1 p.Pro89Gln (c.266C>A) is classified Uncertain significance in BARD1 (ClinVar, Single submitter, 1 submitter; last evaluated 2023-06-07). AlphaMissense: ambiguous (0.4834); Very rare (popmax 0.0011%, sas); Associated with hereditary breast carcinoma.

What condition is associated with BARD1 p.Pro89Gln (c.266C>A)?

BARD1 p.Pro89Gln (c.266C>A) is associated with hereditary breast carcinoma (ClinVar).

How common is BARD1 p.Pro89Gln (c.266C>A) in the general population?

BARD1 p.Pro89Gln (c.266C>A) is very rare (popmax 0.0011%, sas) (gnomAD).

How is Hereditary breast cancer inherited?

Typically Autosomal dominant, Multigenic/multifactorial (Orphanet). A genetic counselor can assess individual risk for a family.

What do computational predictors say about BARD1 p.Pro89Gln (c.266C>A)?

AlphaMissense predicts ambiguous (score 0.4834) — an in-silico prediction, not a clinical call.

BARD1 p.Pro89Gln

c.266C>A · rs780241203 · VCV2752493

Uncertain significance Single submitter

Classification

Uncertain significance

ClinVar

Review

Single submitter ★☆☆☆

ClinVar · 1 submitter

AlphaMissense

ambiguous

0.4834 · ACMG-weighted

gnomAD v4.1

Rare

very rare (popmax 0.0011%, sas)

Missense predictors

1/2 damaging

REVEL, SaProt · AlphaMissense no call

Conditions

hereditary breast carcinoma

Computational evidence

Protein change
AlphaMissense	0.4834	ambiguous
REVEL	0.702	pathogenic-leaning
SaProt	LLR -7.41	tolerated
⇒ REVEL calls this damaging; SaProt does not; AlphaMissense makes no call.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 12	GERP 1.8, phastCons 1
Regional constraint	o/e 1.06	unconstrained · MANE · 81 kb · p 0.077 · regional, not allelic
Overall
CADD	25.7	PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.0011% South Asian · 1/90,976 alleles

Overall 6.84e-05% 1/1,461,102 alleles · very rare

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: BARD1
Protein: p.Pro89Gln
Coding: c.266C>A
MANE Select: NM_000465
dbSNP: rs780241203
Type: single nucleotide variant
Location: chr2:214792395 (GRCh38)
Gene constraint: LOEUF 1.087 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Structure: AlphaFold pLDDT 64.82 · 11 PDB
Residue 89: an α-helix; the 'interaction with brca1' region

Full BARD1 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

hereditary breast carcinoma — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For Hereditary breast cancer (Orphanet):

Inheritance: Autosomal dominant, Multigenic/multifactorial
Onset: Adult, Elderly

Similar variants

BARD1 p.Pro89Arg Uncertain significance ★★ ⚠ same residue
BARD1 p.Pro89Leu Uncertain significance ★★ ⚠ same residue
BARD1 p.Pro89= Conflicting classifications of pathogenicity ★ same residue
BARD1 p.Pro89fs Pathogenic ★★ same residue
BARD1 p.Pro89Ala Uncertain significance ★ ⚠ same residue
BARD1 p.Pro89Thr Uncertain significance ★ ⚠ same residue
BARD1 c.1314+1G>A Pathogenic/Likely pathogenic ★★ same condition
BARD1 c.1396-1G>A Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/bard1-p-pro89gln (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown